Ads
related to: second line treatment for hcc tumor in liver- Unresectable HCC Therapy
Combination Treatment For
Unresectable HCC. Visit Site.
- View The Dosing Regimen
See The Dosing Schedule For A
Unresectable HCC Treatment
- Clinical Study Data
View Data For An Unresectable
Hepatocellular Carcinoma Treatment.
- Official Oncologist Site
Visit Official HCP Site To Learn
About An Immunotherapy Option.
- Safety Info From A Study
See Adverse Reaction Data For A
First-Line Unresectable HCC Therapy
- Connect With A Rep
Have Questions? Find Your Local
Representative To Get Answers.
- Unresectable HCC Therapy
Search results
Results From The WOW.Com Content Network
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
Numerous other molecular targeted drugs are being tested as alternative first- and second-line treatments for advanced HCC, such as lenvatinib and regorafenib. [78] Regorafenib increased survival from 7.8 to 10.6 months in those who had tumor progression while on sorafenib compared to placebo. [6] [79]
Ramucirumab([5]), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. [3] [4] Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist.
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). [7] [8] Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).
Transarterial bland embolization (TAE, also known as HAE) is a catheter-based tumor treatment of the liver.In this procedure, embolizing agents (e.g., polyvinyl alcohol, gelfoam, acrylic copolymer gelatin particles, embospheres) can be delivered through the tumor's feeding artery in order to completely occlude the tumor's blood supply.
Resminostat (4SC-201 or RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents. [1]In 2011, the German drug maker 4SC was granted orphan drug designation for resminostat by the US FDA for the treatment of hepatocellular carcinoma (HCC).
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. [ 9 ] [ 10 ] It is a small-molecule tyrosine-kinase inhibitor (TKI) of c-Met (HGFR) and VEGFR2 , and also inhibits AXL , RET , and FLT3 .
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
Ads
related to: second line treatment for hcc tumor in liver